Top

Published in:

01-07-2021 | Radiotherapy | Original Article

Pretreatment ¹⁸F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma

Authors: Guang Ma, Bingxin Gu, Jiyi Hu, Lin Kong, Jiangang Zhang, Zili Li, Yangbo Xue, Jiade Lu, Junning Cao, Jingyi Cheng, Yingjian Zhang, Shaoli Song, Zhongyi Yang

Published in: Annals of Nuclear Medicine | Issue 7/2021

Abstract

Objective

Our study was to investigate the value of pretreatment ¹⁸F-FDG uptake heterogeneity to predict the prognosis of patients with locally recurrent nasopharyngeal carcinoma (LRNPC) treated by carbon ion radiotherapy (CIRT).

Methods

Twenty-nine LRNPC patients who underwent whole-body ¹⁸F-FDG PET/CT scanning before CIRT were enrolled. Heterogeneity index (HI)-based ¹⁸F-FDG uptake, and the PET/CT traditional parameters, including SUVmax, MTV, and TLG were assessed. Receiver operator characteristics (ROC) determined the best cutoff value, and local recurrence-free survival (LRFS) and progression-free survival (PFS) were evaluated by the Kaplan–Meier method and log-rank test. And the predictive ability was evaluated by the ROC curve. Cox analyses were performed on LRFS and PFS.

Results

In this study, univariate analysis showed that HI was a significant predictor of LRNPC treated by CIRT. HI could be used to predict LRFS and PFS. Patients with HI (≥ 0.81) had a significantly worse prognosis of LRFS (12.25 vs. NR, p = 0.008), and of PFS (10.58 vs. NR, p = 0.014). The AUC and its sensitivity and sensitivity and specificity were 0.75, 84.21% and 70.00% for LRFS and 0.82, 80.95% and 75.00% for PFS, respectively. Multivariate analysis showed that HI was an independent predictor for the LFRS of LRNPC with CIRT.

Conclusion

¹⁸F-FDG uptake heterogeneity may be useful for predicting the prognosis of patients with LRNPC treated by CIRT.

Available only for authorised users

Paul P, Deka H, Malakar AK, Halder B, Chakraborty S. Nasopharyngeal carcinoma: understanding its molecular biology at a fine scale. Eur J Cancer Prev. 2018;27(1):33–41.PubMedCrossRef

Hu J, Bao C, Gao J, Guan X, Hu W, Yang J, et al. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: initial results. Cancer. 2018;124(11):2427–37.PubMedPubMedCentralCrossRef

Kong F, Zhou J, Du C, He X, Kong L, Hu C, et al. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. BMC Cancer. 2018;18(1):1139.PubMedPubMedCentralCrossRef

Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019;79:101890.PubMedCrossRef

Hua YJ, Han F, Lu LX, Mai HQ, Guo X, Hong MH, et al. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer. 2012;48(18):3422–8.PubMedCrossRef

Han F, Zhao C, Huang SM, Lu LX, Huang Y, Deng XW, et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2012;24(8):569–76.CrossRef

Qiu S, Lin S, Tham IW, Pan J, Lu J, Lu JJ. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2012;83(2):676–83.PubMedCrossRef

Ng WT, Ngan RKC, Kwong DLW, Tung SY, Yuen KT, Kam MKM, et al. Prospective, multicenter, phase 2 trial of induction chemotherapy followed by bio-chemoradiotherapy for locally advanced recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(3):630–8.PubMedCrossRef

Poon D, Yap SP, Wong ZW, Cheung YB, Leong SS, Wee J, et al. Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2004;59(5):1312–8.PubMedCrossRef

10.

Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 2012;42(8):670–85.PubMedPubMedCentralCrossRef

11.

Lomax AJ. Charged particle therapy: the physics of interaction. Cancer J. 2009;15(4):285–91.PubMedCrossRef

12.

Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25(8):953–64.PubMedCrossRef

13.

Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased ¹⁸F-FDG uptake. J Nucl Med. 2005;46(10):1753–9.PubMed

14.

Gong C, Ma G, Hu X, Zhang Y, Wang Z, Zhang J, et al. Pretreatment ¹⁸F-FDG uptake heterogeneity predicts treatment outcome of first-line chemotherapy in patients with metastatic triple-negative breast cancer. Oncologist. 2018;23(10):1144–52.PubMedPubMedCentralCrossRef

15.

Kang SR, Song HC, Byun BH, Oh JR, Kim HS, Hong SP, et al. Intratumoral metabolic heterogeneity for prediction of disease progression after concurrent chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer. Nucl Med Mol Imaging. 2014;48(1):16–25.PubMedCrossRef

16.

Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline ¹⁸F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52(3):369–78.PubMedPubMedCentralCrossRef

17.

Huang Y, Feng M, He Q, Yin J, Xu P, Jiang Q, et al. Prognostic value of pretreatment ¹⁸F-FDG PET/CT for nasopharyngeal carcinoma patients. Medicine. 2017;96(17):e6721.PubMedPubMedCentralCrossRef

18.

Mohandas A, Marcus C, Kang H, Truong MT, Subramaniam RM. FDG PET/CT in the management of nasopharyngeal carcinoma. AJR Am J Roentgenol. 2014;203(2):W146-157.PubMedCrossRef

19.

Alessi A, Lorenzoni A, Cavallo A, Padovano B, Iacovelli NA, Bossi P, et al. Role of pretreatment ¹⁸F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. Radiol Med (Torino). 2019;124(5):414–21.CrossRef

20.

Yang Z, Shi Q, Zhang Y, Pan H, Yao Z, Hu S, et al. Pretreatment ¹⁸F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma-a retrospective study. Radiat Oncol. 2015;10:4.PubMedPubMedCentralCrossRef

21.

Gu B, Zhang J, Ma G, Song S, Shi L, Zhang Y, et al. Establishment and validation of a nomogram with intratumoral heterogeneity derived from ¹⁸F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma. BMC Cancer. 2020;20(1):37.PubMedPubMedCentralCrossRef

22.

Tello Galán MJ, García Vicente AM, Pérez Beteta J, Amo Salas M, Jiménez Londoño GA, Pena Pardo FJ, et al. Global heterogeneity assessed with 18F-FDG PET/CT Relation with biological variables and prognosis in locally advanced breast cancer. Rev Esp Med Nucl Imagen Mol. 2019;38(5):290–7.PubMed

23.

Almobarak AA, Jebreel AB, Abu-Zaid A. Molecular targeted therapy in the management of recurrent and metastatic nasopharyngeal carcinoma: a comprehensive literature review. Cureus. 2019;11(3):e4210.PubMedPubMedCentral

24.

Otero J, Felis I, Ardid M, Herrero A. Acoustic localization of bragg peak proton beams for hadrontherapy monitoring. Sensors (Basel). 2019;19(9):1971.CrossRef

25.

Mohamad O, Sishc BJ, Saha J, Pompos A, Rahimi A, Story MD, et al. Carbon ion radiotherapy: a review of clinical experiences and preclinical research, with an emphasis on DNA damage/repair. Cancers (Basel). 2017;9(6):66.CrossRef

26.

Combs SE, Kessel K, Habermehl D, Haberer T, Jäkel O, Debus J. Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta Oncol. 2013;52(7):1504–9.PubMedCrossRef

27.

Takahashi W, Nakajima M, Yamamoto N, Yamashita H, Nakagawa K, Miyamoto T, et al. A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC). Cancer. 2015;121(8):1321–7.PubMedCrossRef

28.

Makishima H, Yasuda S, Isozaki Y, Kasuya G, Okada N, Miyazaki M, et al. Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: a dose escalation study. Cancer Sci. 2019;110(1):303–9.PubMed

29.

Zhang Y, Li P, Yu Q, Wu S, Chen X, Zhang Q, et al. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer. Radiat Oncol. 2019;14(1):94.PubMedPubMedCentralCrossRef

30.

Matsunobu A, Imai R, Kamada T, Imaizumi T, Tsuji H, Tsujii H, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012;118(18):4555–63.PubMedCrossRef

31.

Zhang H, Li S, Wang XH, Li Q, Wei SH, Gao LY, et al. Results of carbon ion radiotherapy for skin carcinomas in 45 patients. Br J Dermatol. 2012;166(5):1100–6.PubMedCrossRef

32.

Karasawa K, Omatsu T, Arakawa A, Yamamoto N, Ishikawa T, Saito M, et al. A phase I clinical trial of carbon ion radiotherapy for stage I breast cancer: clinical and pathological evaluation. J Radiat Res. 2019;60(3):342–7.PubMedPubMedCentralCrossRef

33.

Irie D, Okonogi N, Wakatsuki M, Kato S, Ohno T, Karasawa K, et al. Carbon-ion radiotherapy for inoperable endometrial carcinoma. J Radiat Res. 2018;59(3):309–15.PubMedPubMedCentralCrossRef

34.

Mohamad O, Imai R, Kamada T, Nitta Y, Araki N. Carbon ion radiotherapy for inoperable pediatric osteosarcoma. Oncotarget. 2018;9(33):22976–85.PubMedPubMedCentralCrossRef

35.

Malouff TD, Mahajan A, Krishnan S, Beltran C, Seneviratne DS, Trifiletti DM. Carbon ion therapy: a modern review of an emerging technology. Front Oncol. 2020;10:82.PubMedPubMedCentralCrossRef

36.

Helm A, Ebner DK, Tinganelli W, Simoniello P, Bisio A, Marchesano V, et al. Combining heavy-ion therapy with immunotherapy: an update on recent developments. Int J Part Ther. 2018;5(1):84–93.PubMedPubMedCentralCrossRef

37.

Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJR. Quantifying tumour heterogeneity in ¹⁸F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40(1):133–40.PubMedCrossRef

38.

Shirai K, Abe T, Saitoh JI, Mizukami T, Irie D, Takakusagi Y, et al. Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy. Oncol Lett. 2017;13(6):4420–6.PubMedPubMedCentralCrossRef

39.

Shrestha S, Higuchi T. Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy. Eur J Nucl Med Mol Imaging. 2020;47(5):1220–7.PubMedCrossRef

40.

Lin AJ, Dehdashti F, Grigsby PW. Molecular imaging for radiotherapy planning and response assessment for cervical cancer. Semin Nucl Med. 2019;49(6):493–500.PubMedCrossRef

41.

Qu H, Huang Y, Zhao S, Zhou Y, Lv W. Prognostic value of Epstein–Barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol. 2020;277(1):9–18.PubMedCrossRef

Title: Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma
Authors: Guang Ma
Bingxin Gu
Jiyi Hu
Lin Kong
Jiangang Zhang
Zili Li
Yangbo Xue
Jiade Lu
Junning Cao
Jingyi Cheng
Yingjian Zhang
Shaoli Song
Zhongyi Yang
Publication date: 01-07-2021
Publisher: Springer Singapore
Keyword: Radiotherapy
Published in: Annals of Nuclear Medicine / Issue 7/2021
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-021-01621-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pretreatment ¹⁸F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2021

Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)

Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy

Monte Carlo simulation of the acquisition conditions for 177Lu molecular imaging of hepatic tumors

18F-FDG cerebellum/liver index as a prognostic factor for progression-free survival in diffuse large B-cell lymphoma

Measuring myocardial blood flow with 82rubidium using Gjedde–Patlak–Rutland graphical analysis

The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review